Journal
GENES
Volume 8, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/genes8060151
Keywords
MYC; deregulation; cancer; gene amplification; translocation; enhancers; cell signaling
Categories
Funding
- Canadian Institutes of Health Research
- Canada Research Society
- Leukemia Lymphoma Society of Canada
- Collaborative Health Research Projects Programs
- Canada Research Chairs Program
- Canadian Breast Cancer Foundation
- Natural Sciences and Engineering Research Council of Canada
Ask authors/readers for more resources
MYC regulates a complex biological program by transcriptionally activating and repressing its numerous target genes. As such, MYC is a master regulator of many processes, including cell cycle entry, ribosome biogenesis, and metabolism. In cancer, the activity of the MYC transcriptional network is frequently deregulated, contributing to the initiation and maintenance of disease. Deregulation often leads to constitutive overexpression of MYC, which can be achieved through gross genetic abnormalities, including copy number alterations, chromosomal translocations, increased enhancer activity, or through aberrant signal transduction leading to increased MYC transcription or increased MYC mRNA and protein stability. Herein, we summarize the frequency and modes of MYC deregulation and describe both well-established and more recent findings in a variety of cancer types. Notably, these studies have highlighted that with an increased appreciation for the basic mechanisms deregulating MYC in cancer, new therapeutic vulnerabilities can be discovered and potentially exploited for the inhibition of this potent oncogene in cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available